Corbus Pharmaceuticals reports results from Phase 1a study of CRB-913 in obesity

Corbus Pharmaceuticals (CRBP) announced the completion of the single ascending dose, or SAD, and multiple ascending dose, or MAD, Phase 1a study of CRB-913 and the initiation of a Phase 1b dose-range finding study, with completion expected in summer 2026. CRB-913 is a small molecule CB1 inverse agonist targeting chronic obesity management. The Phase 1a study assessed the safety, tolerability, and pharmacokinetics of escalating once-daily doses of CRB-913. No serious treatment-emergent adverse events were reported in the SAD/MAD study. CRB-913 was not associated with GI intolerability. There were no reported cases of nausea, vomiting, or constipation and only a single case of mild diarrhea. Daily neuropsychiatric assessments remained stable and negative at all time points for all participants. No cases of suicidality, depression, or insomnia were reported in the study. The PK profile for CRB-913 was established and was found to be suitable for a once-daily oral dosing. In the dedicated obese MAD cohort, all CRB-913-treated participants, and none in the placebo group, experienced weight loss. The CRB-913-treated participants achieved a mean 2.9% placebo-adjusted weight loss by Day 14. Individual participant weight loss ranged from 1.3% to 4.3%. Weight loss started early and deepened with time. Notably, several participants treated with CRB-913 reported reduction in food-related thoughts and cravings.